Erba Mannheim Acquires Maxmat for Diagnostics Analyzers and Advanced Development
By LabMedica International staff writers Posted on 25 Oct 2015 |
Through its Czech subsidiary Erba Lachema, Erba Mannheim (Mannheim, Germany) has expanded its portfolio by acquiring Maxmat SA, France, a company emphasizing development and manufacturing of medical laboratory devices based on original patented technologies.
On September 21, 2015, Erba Mannheim successfully completed its acquisition of Maxmat, whose blood analyzers are used in clinical laboratories in Western Europe, the USA, and other countries. Maxmat SA France has been renamed to Erba Diagnostics France SARL (Montpellie, France). Erba Diagnostics France will benefit the entire Erba group with its capabilities and knowhow in the field of design and development of analyzers that perform multiple functions in a laboratory spanning different segments of biochemistry, hemostasis, and immunology. Among its product-line is a revolutionary multi-analyzer that can conduct hundreds of different biochemistry, coagulation, and immunology tests on a sample.
Jaroslav Rehurek, Managing Director of Erba Lachema, said: “For us, Maxmat represents a great potential in the area of development of medical devices, and therefore it is supposed to contribute to additional growth of our company. Moreover, we are sure that its analyzers will soon find customers in our markets. Furthermore, the acquisition offers a highly favorable synergy with the current portfolio of our company.”
The acquisition will help shrink development timelines for new advanced technologies and to fulfill the needs of diagnostic laboratories. Erba Diagnostics France (formerly Maxmat SA) will also improve the group’s presence in France and French-speaking North African countries.
Mr. Suresh Vazirani, Chairman and Managing Director of Erba’s Transasia Bio-Medicals Ltd, stated, “We are excited about the new opportunities that are offered by this strategic acquisition. This acquisition will strengthen the group’s plans to emerge as a global leader in IVD.” Erba Group and Erba Diagnostics France (formerly Maxmat SA) have drawn up growth plans based on achieving economies of scale, widening product offering, creating synergy through intra-group coordination, and strengthening after-sales service support and distribution network.
Related Links:
Erba Mannheim
Erba Diagnostics France
On September 21, 2015, Erba Mannheim successfully completed its acquisition of Maxmat, whose blood analyzers are used in clinical laboratories in Western Europe, the USA, and other countries. Maxmat SA France has been renamed to Erba Diagnostics France SARL (Montpellie, France). Erba Diagnostics France will benefit the entire Erba group with its capabilities and knowhow in the field of design and development of analyzers that perform multiple functions in a laboratory spanning different segments of biochemistry, hemostasis, and immunology. Among its product-line is a revolutionary multi-analyzer that can conduct hundreds of different biochemistry, coagulation, and immunology tests on a sample.
Jaroslav Rehurek, Managing Director of Erba Lachema, said: “For us, Maxmat represents a great potential in the area of development of medical devices, and therefore it is supposed to contribute to additional growth of our company. Moreover, we are sure that its analyzers will soon find customers in our markets. Furthermore, the acquisition offers a highly favorable synergy with the current portfolio of our company.”
The acquisition will help shrink development timelines for new advanced technologies and to fulfill the needs of diagnostic laboratories. Erba Diagnostics France (formerly Maxmat SA) will also improve the group’s presence in France and French-speaking North African countries.
Mr. Suresh Vazirani, Chairman and Managing Director of Erba’s Transasia Bio-Medicals Ltd, stated, “We are excited about the new opportunities that are offered by this strategic acquisition. This acquisition will strengthen the group’s plans to emerge as a global leader in IVD.” Erba Group and Erba Diagnostics France (formerly Maxmat SA) have drawn up growth plans based on achieving economies of scale, widening product offering, creating synergy through intra-group coordination, and strengthening after-sales service support and distribution network.
Related Links:
Erba Mannheim
Erba Diagnostics France
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance